Achieve life sciences announces pricing of $20 million underwritten public offering

Seattle, wa and vancouver, bc / accesswire / may 25, 2021 / achieve life sciences, inc. (nasdaq:achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 2,857,143 shares of its common stock at a price to the public of $7.00 per share. achieve has also granted the underwriters a 30-day option to purchase up to an additional 428,571 shares of common stock in connection with the public offering.
ACHV Ratings Summary
ACHV Quant Ranking